MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

Exact Sciences ($EXAS) now has something that diagnostics companies find increasingly hard to win: Medicare coverage, obtained for its new cutting-edge colorectal ...

On Tuesday, Exact Sciences (NASDAQ:EXAS) received a favorable final decision from the Centers for Medicare & Medicaid Services (CMS) regarding the Medicare pricing for its next-generation assay, ...

On Tuesday, Stifel reaffirmed its Buy rating and $67.00 price target for Exact Sciences (NASDAQ:EXAS), following the announcement of a Medicare reimbursement increase for the company's Cologuard Plus ...

Shares of Exact Sciences (NASDAQ:EXAS) traded higher on Wednesday after TD Cowen said that the company is seeking a 25% price hike from Medicare for its next-generation colorectal cancer screening ...

Passage of MCED legislation marks major milestone for early cancer detection Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Exact Sciences anticipates a swift transition for Medicare fee-for-service, which accounts for 15-20% of Cologuard volumes, to the new rate, beginning one month after the initial orders expected early ...